Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

NCT ID: NCT04362462

Last Updated: 2020-04-27

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 120 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-03-05
• Study Completion Date: 2023-12-31

Brief Summary

Neoadjuvant chemotherapy (NACT) can induce complete pathologic response (pCR) in approximately 35-55% of patient with triple-negative breast cancer (TNBC). These patients have excellent long term survivals. On the other hand patients with residual disease exhibit a high rate of local or metastatic. Although it has been successful in some regards, randomized trials have shown similar rates of mortality between patients receiving NACT and adjuvant chemotherapy (ACT). The goal of this study is to understand the molecular biology (gene expression signature) driving treatment-resistant TNBC. The investigators are planning to identify targetable genetic alterations which may help to optimize adjuvant therapy for the patient with residual TNBC.

Detailed Description

In this study, investigators will understand the clinical relevance of genomic heterogeneity of triple-negative breast cancer by determining pathological complete response (pCR) rates after NACT, based on genomic profiling of individual tumors. Investigators will identify new genomic alterations in patients with residual TNBC as well as in patients who develop metastatic disease within 24 months after completion of all appropriate therapies. Investigators will demonstrate unique genomic alteration, and we will identify new tumor markers in Hispanic/Latino (H/L) women with TNBC.

Inclusion Criteria:

This study aims to include all patients with early stage (I-III) TNBC who received NACT and subsequently underwent surgical treatment (mastectomy or lumpectomy) or women with triple-negative breast cancer who progressed and developed metastatic disease within 24 months after all appropriate therapies.

1. Age > 18 or <86 years of age, for Hispanic/Latino women we will use the National Advisory Committee on Racial, Ethnic and Other populations NAC definition which is (the ethnonyms "Hispanic" and "Latino" to refer collectively to the inhabitants of the United States of America who are of Latin American or Spanish origin-that is, Latino or Hispanic Americans).

2. Pre- and Post - menopausal women with histologically confirmed hormonal receptor negative (ER and/or PR <1%), Her2-neu - negative (by IHC or/and FISH) invasive breast cancer stages I - III or with metastatic triple-negative breast cancer (if develop metastatic disease during the chemotherapy or within 24 months after completion of all appropriate treatments).

3. Patients must be eligible for NACT, and surgical lumpectomy or mastectomy.

4. All patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with Institutional and Federal guidelines.

Exclusion Criteria:

1. Women < 18 or >86 years of age

2. ER/PR- positive, Her-2 neu - positive breast cancer.

Conditions

Triple-negative Breast Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Eligibility Criteria

Inclusion Criteria

1. Age > 18 or <86 years of age, for Hispanic/Latino women we will use the National Advisory Committee on Racial, Ethnic and Other populations NAC definition which is (the ethnonyms "Hispanic" and "Latino" to refer collectively to the inhabitants of the United States of America who are of Latin American or Spanish origin-that is, Latino or Hispanic Americans).

2. Pre- and Post - menopausal women with histologically confirmed hormonal receptor negative (ER and/or PR <1%), Her2-neu - negative (by IHC or/and FISH) invasive breast cancer stages I - III or with metastatic triple-negative breast cancer (if develop metastatic disease during the chemotherapy or within 24 months after completion of all appropriate treatments).

3. Patient must be eligible for neo-adjuvant chemotherapy, and surgical lumpectomy or mastectomy.

4. All patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with Institutional and Federal guidelines.

Exclusion Criteria

1. Women < 18 or >86 years of age

2. ER/PR- positive, Her-2 neu - positive breast cancer.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 86 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Texas Tech University Health Sciences Center, El Paso

OTHER

Sponsor Role: lead

Responsible Party

Alexander Philipovskiy

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Alexander Philipovskiy, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Texas Tech University Health Sciences Center, El Paso

Locations

Texas Tech University Health Sciences Center- El Paso

El Paso, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Alexander Philipovskiy, MD, PhD

Role: CONTACT

alexander.philipovskiy@ttuhsc.edu

9158155195

Brenda Castillo, BS

Role: CONTACT

brenda.castillo@ttuhsc.edu

9152154831

Facility Contacts

Alexander Philipovskiy, MD, PhD

Role: primary

alexander.philipovskiy@ttuhsc.edu

915-215-5195

Brenda Castillo, BS

Role: backup

brenda.castillo@ttuhsc.edu

9152154831

Other Identifiers

E19059

Identifier Type: -

Identifier Source: org_study_id